摘要
绿原酸(CGA)显示了肝癌、乳腺癌和皮肤癌的治疗可能性。与CGA刺激的癌细胞表现出差异表达的转录因子和调节分子,但分子的分子靶标是未知的。对CGA生原体的元素与Curcumin叠加了0.90最大公共子结构分。分子模拟研究进一步表明,CGA与PKC与氨基酸残基结合位点广泛互动C1B域。它结合PKC是浓度依赖性解离常数KD,28.84±3.95μM. pkc-cga复杂稳定,失真最小的三维结构和维持氢键配体和受体之间的模拟期间。与CGA刺激的细胞会导致从细胞质到质膜12.1°C 0.56% PKC易位。它扰乱了细胞周期使癌细胞在G1期S期细胞减少。绿原酸具有杀灭癌细胞以剂量依赖的方式与75.88±4.54μμg/ml和52.5±4.72μg/mL对MDA-MB-231和MCF-7细胞的IC50分别为。它在肿瘤细胞中诱导细胞凋亡的AO /溴化乙锭染色和DNA梯状条带明显降解给。在癌细胞凋亡的线粒体途径中涉及的线粒体膜电位和释放进入细胞质减少,支持细胞。因此,目前的研究已经建立了PKC作为一个重要的信号分子所观察到的抗癌作用的CGA,并提供动力,设计更好的CGA类似物,提高抗癌潜力对恶性肿瘤。
关键词: 激动剂,肿瘤,细胞周期,姜黄素,细胞色素C,对接,线粒体,蛋白激酶C,PMA,易位。
Current Molecular Medicine
Title:Evidence of PKC Binding and Translocation to Explain the Anticancer Mechanism of Chlorogenic Acid in Breast Cancer Cells
Volume: 17 Issue: 1
关键词: 激动剂,肿瘤,细胞周期,姜黄素,细胞色素C,对接,线粒体,蛋白激酶C,PMA,易位。
摘要: Chlorogenic acid (CGA) exhibits potentials towards liver, breast and skin cancer. Cancer cells stimulated with CGA exhibits differential expression of transcriptional factors and regulatory molecules but the molecular target of the molecule is not known. Superposition of biophoric elements of CGA with Curcumin gives maximum common substructure score of 0.90. Molecular modeling studies further suggest that CGA fits into the C1b domain of PKC with extensive interaction with residues lining binding site. It binds PKC in a concentration dependent manner with dissociation constant KD, 28.84±3.95 μM. PKC-CGA complex is stable with minimal distortion to the 3-D structure and maintains the hydrogen bonding between ligand and receptor during simulation period. Cells stimulated with CGA causes 12.1 ± 0.56% PKC translocation from the cytosol to the plasma membrane. It disturbs the cell cycle and arrest the cancer cell at the G1 phase with a reduction in S-phase. Chlorogenic acid exhibits killing of cancer cells in a dose-dependent manner with an IC50 of 75.88 ± 4.54μg/ml and 52.5 ± 4.72μg/ml towards MDAMB-231 and MCF-7 cells respectively. It induces apoptosis in cancer cells as evident by AO/EtBr staining and degradation of genomic DNA to give a laddering pattern. Apoptosis in cancer cells involves mitochondrial pathway as supported by a reduction in mitochondrial potentials and release of cyt-C into the cytosol. Hence, the current study has established PKC as an important signaling molecule to the observed anti-cancer effects of CGA and provides the impetus to design better CGA analogs for improved anti-cancer potential against the malignant tumor.
Export Options
About this article
Cite this article as:
Evidence of PKC Binding and Translocation to Explain the Anticancer Mechanism of Chlorogenic Acid in Breast Cancer Cells, Current Molecular Medicine 2017; 17 (1) . https://dx.doi.org/10.2174/1566524017666170209160619
DOI https://dx.doi.org/10.2174/1566524017666170209160619 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets Seeds of Peganum Harmala L. Chemical Analysis, Antimalarial and Antioxidant Activities, and Cytotoxicity Against Human Breast Cancer Cells
Medicinal Chemistry Predictive Diagnostic Pathology in the Target Therapy Era in Breast Cancer
Current Drug Targets Molecular Chaperones as Rational Drug Targets for Parkinsons Disease Therapeutics
CNS & Neurological Disorders - Drug Targets Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Strategies for Preparing Different Types of Lipid Polymer Hybrid Nanoparticles in Targeted Tumor Therapy
Current Pharmaceutical Design Cell Dormancy and Tumor Refractory
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design An Integrative Informatics Approach to Explain the Mechanism of Action of N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors
Current Computer-Aided Drug Design Muscular Gene Transfer Using Nonviral Vectors
Current Gene Therapy Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Current Pharmaceutical Design Homology Modeling of MDR1 Gene MDR1_ENTHI of <i>E. histolytica</i> & its Molecular Docking with Anti-Entamoeba Histolytica Agents
Current Topics in Medicinal Chemistry Transcriptome Analysis of FEN1 Knockdown HEK293T Cell Strain Reveals Alteration in Nucleic Acid Metabolism, Virus Infection, Cell Morphogenesis and Cancer Development
Combinatorial Chemistry & High Throughput Screening Small Molecule Integrin Antagonists in Cancer Therapy
Mini-Reviews in Medicinal Chemistry A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates
Current Neuropharmacology Editor’s Perspective: Metabolomics Currently
Current Metabolomics SELDI Protein Chip Technology for the Detection of Serum Biomarkers for Liver Disease
Protein & Peptide Letters Immune Checkpoint Inhibitors in the Treatment of Cancer
Current Reviews in Clinical and Experimental Pharmacology Synthesis and In Vitro Cytotoxic Activity Evaluation of Novel Mannich Bases and Modified AZT Derivatives Possessing Mannich Base Moieties via Click Chemistry
Letters in Drug Design & Discovery Mesenchymal Stem Cell as a Potential Therapeutic for Inflammatory Bowel Disease- Myth or Reality?
Current Stem Cell Research & Therapy